{"id":4887,"date":"2019-10-09T13:00:39","date_gmt":"2019-10-09T11:00:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/"},"modified":"2019-10-09T13:00:39","modified_gmt":"2019-10-09T11:00:39","slug":"neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/","title":{"rendered":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 &#8211; Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4845471\/neuronal-acetylcholine-receptor-subunit-alpha-7?utm_source=BW&#038;utm_medium=PressRelease&#038;utm_code=j3mcdx&#038;utm_campaign=1306276+-+Neuronal+Acetylcholine+Receptor+Subunit+Alpha+7+Pipeline+Review%2C+H2+2019+-+Therapy+Areas+Covered+Such+as+Central+Nervous+System%2C+Cardiovascular%2C+Immunology%2C+Metabolic+Disorders+and+Oncology&#038;utm_exec=anwr281prd\" shape=\"rect\" rel=\"noopener noreferrer\">&#8220;Neuronal Acetylcholine Receptor Subunit Alpha 7 &#8211; Pipeline Review, H2 2019&#8221;<\/a> drug pipelines has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/5\/ResearchAndMarkets_800px.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg\"><\/a><\/p>\n<p>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities\/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 &#8211; Pipeline Review, H2 2019, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.\n<\/p>\n<p>\nSimilarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology which include indications Alzheimer&#8217;s Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Bipolar Disorder (Manic Depression), Pain, Parkinson&#8217;s Disease, Smoking Cessation, Traumatic Brain Injury, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy\/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer&#8217;s Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Neuropathic Pain (Neuralgia), Obesity, Panic Disorders and Post-Traumatic Stress Disorder (PTSD).\n<\/p>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<ul>\n<li>\nThe report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)\n<\/li>\n<li>\nThe report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities\/research institutes based on information derived from company and industry-specific sources\n<\/li>\n<li>\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages\n<\/li>\n<li>\nThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&#038;D brief, licensing and collaboration details &#038; other developmental activities\n<\/li>\n<li>\nThe report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects\n<\/li>\n<li>\nThe report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type\n<\/li>\n<li>\nThe report summarizes all the dormant and discontinued pipeline projects\n<\/li>\n<li>\nThe report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to buy<\/strong>\n<\/p>\n<ul>\n<li>\nGain strategically significant competitor information, analysis, and insights to formulate effective R&#038;D strategies\n<\/li>\n<li>\nIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage\n<\/li>\n<li>\nIdentify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)\n<\/li>\n<li>\nIdentify the use of drugs for target identification and drug repurposing\n<\/li>\n<li>\nIdentify potential new clients or partners in the target demographic\n<\/li>\n<li>\nDevelop strategic initiatives by understanding the focus areas of leading companies\n<\/li>\n<li>\nPlan mergers and acquisitions effectively by identifying key players and it&#8217;s most promising pipeline therapeutics\n<\/li>\n<li>\nDevise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape\n<\/li>\n<li>\nDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered: <\/strong>\n<\/p>\n<ul>\n<li>\nIntroduction\n<\/li>\n<li>\nReport Coverage\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Overview\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Therapeutics Development\n<\/li>\n<li>\nProducts under Development by Stage of Development\n<\/li>\n<li>\nProducts under Development by Therapy Area\n<\/li>\n<li>\nProducts under Development by Indication\n<\/li>\n<li>\nProducts under Development by Companies\n<\/li>\n<li>\nProducts under Development by Universities\/Institutes\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Therapeutics Assessment\n<\/li>\n<li>\nAssessment by Mechanism of Action\n<\/li>\n<li>\nAssessment by Route of Administration\n<\/li>\n<li>\nAssessment by Molecule Type\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Companies Involved in Therapeutics Development\n<\/li>\n<li>\nBionomics Ltd\n<\/li>\n<li>\nBristol-Myers Squibb Co\n<\/li>\n<li>\nCoMentis Inc\n<\/li>\n<li>\nDanPET AB\n<\/li>\n<li>\nEpigen Biosciences Inc\n<\/li>\n<li>\nJohnson &#038; Johnson\n<\/li>\n<li>\nKatexco Pharmaceuticals Corp\n<\/li>\n<li>\nMerck &#038; Co Inc\n<\/li>\n<li>\nNeuro Bio Ltd\n<\/li>\n<li>\nSK Biopharmaceuticals Co Ltd\n<\/li>\n<li>\nVanda Pharmaceuticals Inc\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Drug Profiles\n<\/li>\n<li>\nAVL-3288 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nAVL-8168 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nBMS-910731 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nBNC-210 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nBNC-375 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nEPGN-1137 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nGln-1062 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nGTS-21 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nJNJ-39393406 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nNBP-14 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nNS-12877 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nSKL-20540 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nSmall Molecule to Agonize CB1, CB2 and CHRNA7 for Inflammatory Diseases &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nSmall Molecules to Agonize CHRNA7 for Central Nervous System &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nSmall Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nVQW-765 &#8211; Drug Profile\n<\/li>\n<li>\nProduct Description\n<\/li>\n<li>\nMechanism Of Action\n<\/li>\n<li>\nR&#038;D Progress\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Dormant Products\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Discontinued Products\n<\/li>\n<li>\nNeuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) &#8211; Product Development Milestones\n<\/li>\n<li>\nFeatured News &#038; Press Releases\n<\/li>\n<li>\nAppendix\n<\/li>\n<\/ul>\n<p>\nFor more information about this drug pipelines report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4845471\/neuronal-acetylcholine-receptor-subunit-alpha-7?utm_source=BW&#038;utm_medium=PressRelease&#038;utm_code=j3mcdx&#038;utm_campaign=1306276+-+Neuronal+Acetylcholine+Receptor+Subunit+Alpha+7+Pipeline+Review%2C+H2+2019+-+Therapy+Areas+Covered+Such+as+Central+Nervous+System%2C+Cardiovascular%2C+Immunology%2C+Metabolic+Disorders+and+Oncology&#038;utm_exec=anwr281prd\" shape=\"rect\" rel=\"noopener noreferrer\">https:\/\/www.researchandmarkets.com\/r\/b8bbw0<\/a>\n<\/p>\n<div style=\"display:none;\">\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20191009005338r1&#038;sid=web02&#038;distro=nx&#038;lang=en\" style=\"width:0;height:0\"><span class=\"bwct31415\"><\/span><\/p>\n<p><b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;&#x61;&#x72;&#x6b;&#x65;&#x74;&#x73;&#x2e;&#x63;&#x6f;&#x6d;\" shape=\"rect\" rel=\"noopener noreferrer\">&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;&#x61;&#x72;&#x6b;&#x65;&#116;&#115;&#46;&#99;&#111;&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<p>\n\u00a0\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neuronal Acetylcholine Receptor Subunit Alpha 7 &#8211; Pipeline Review, H2 2019&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities\/institutes. The latest report Neuronal Acetylcholine &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-4887","6":"format-standard","7":"category-allgemein"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neuronal Acetylcholine Receptor Subunit Alpha 7 &#8211; Pipeline Review, H2 2019&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities\/institutes. The latest report Neuronal Acetylcholine ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-09T11:00:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 &#8211; Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2019-10-09T11:00:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/\"},\"wordCount\":952,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005338\\\/en\\\/371054\\\/21\\\/ResearchAndMarkets_800px.jpg\",\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/\",\"name\":\"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005338\\\/en\\\/371054\\\/21\\\/ResearchAndMarkets_800px.jpg\",\"datePublished\":\"2019-10-09T11:00:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005338\\\/en\\\/371054\\\/21\\\/ResearchAndMarkets_800px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005338\\\/en\\\/371054\\\/21\\\/ResearchAndMarkets_800px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 &#8211; Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/","og_locale":"en_US","og_type":"article","og_title":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neuronal Acetylcholine Receptor Subunit Alpha 7 &#8211; Pipeline Review, H2 2019&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities\/institutes. The latest report Neuronal Acetylcholine ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/","og_site_name":"Pharma Trend","article_published_time":"2019-10-09T11:00:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 &#8211; Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology &#8211; ResearchAndMarkets.com","datePublished":"2019-10-09T11:00:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/"},"wordCount":952,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg","articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/","url":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/","name":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 - Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg","datePublished":"2019-10-09T11:00:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20191009005338\/en\/371054\/21\/ResearchAndMarkets_800px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2019-therapy-areas-covered-such-as-central-nervous-system-cardiovascular-immunology-metabolic-disorders-and-oncology-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neuronal Acetylcholine Receptor Subunit Alpha 7 Pipeline Review, H2 2019 &#8211; Therapy Areas Covered Such as Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders and Oncology &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=4887"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4887\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=4887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=4887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=4887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}